Project Grant R21EY035425
Award Date
9/30/23
Completion Date
8/31/25
Dollars Obligated
$480K
Federal Agency
National Eye Institute
Federal Grant Program
93.867
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
The National Eye Institute (NEI) has awarded a $2,305,702 Project Grant (CFDA 93.867 - Vision Research) to Vanderbilt University Medical Center to conduct integrative multi-omics research to discover molecular pathways associated with diabetic retinopathy (DR). The project aims to quantify differential transcript and metabolite abundance between participants with type 2 diabetes with and without clinical diagnosis of DR in the Cameron County Hispanic Cohort, and replicate findings in the...
The National Eye Institute (NEI) awarded a $634,731 Project Grant (CFDA 93.867 Vision Research) to the University of Alabama at Birmingham (UAB) to develop an RXR-based therapy for treating diabetic retinopathy. The funding will support research to evaluate the therapeutic impact of intravitreal delivery of RXR agonist microparticles (UAB126-MP and UAB30-MP) to prevent and reverse diabetic retinopathy in mouse models and human retinal cell cultures. The goal is to determine if this targeted...
The National Eye Institute awarded the University of Southern California a $443,408 federal Project Grant under the Vision Research program (CFDA 93.867) to develop a novel therapeutic intervention using oxygen nanobubbles to treat retinal ischemia and prevent vision loss. The project aims to: 1) formulate a consistent oxygen nanobubble formulation and evaluate its physical/biochemical properties; 2) identify the optimal administration timing to improve ischemia-induced impairments of retinal...
The National Eye Institute (NEI) awarded a $184,117 Project Grant (CFDA 93.867 - Vision Research) to Oakland University to investigate the role of G-protein coupled receptors GPR31 and GPR39 in the pathogenesis of diabetic retinopathy. The research aims to determine the affinities and substrate specificities of these receptors for the 12/15-lipoxygenase metabolites 12-HETE and 15-HETE, and to examine the effects of GPR31 and GPR39 gain-or-loss-of-function on retinal endothelial cells and...
This Project Grant award from the National Eye Institute (NEI), under the agency's Vision Research program (CFDA 93.867), aims to advance the state of the art in ophthalmic imaging to improve diagnosis and treatment of diabetic retinopathy (DR). The $204,305 award, spanning June 2024 to December 2026, supports the development of two key technologies: An adapted robotically-aligned optical coherence tomography (RAOCT) system that can provide automated, volumetric imaging and measurement of the...
This Project Grant award from the National Eye Institute (NEI), under the CFDA 93.867 Vision Research program, is funding a research study at Augusta University Research Institute, Inc. to investigate the role of HDAC6 and SIRT1 in the development of diabetic retinopathy, a leading cause of blindness in adults with diabetes. The $469,854 grant, awarded on September 1, 2024, will support a four-year project to examine how altered SIRT1-HDAC6 balance leads to exosome-mediated retinal vascular...
This $241,500 Project Grant award from the National Eye Institute (NEI) under the Vision Research federal grant program (CFDA 93.867) will evaluate the impact of patient, neighborhood, and community characteristics on screening and monitoring adherence for diabetic retinopathy (DR) among Medicare beneficiaries with diabetes. The study aims to 1) identify factors associated with adherence to recommended DR screening intervals, and 2) identify factors associated with adherence to recommended DR...
This federal Project Grant award from the National Eye Institute (CFDA 93.867 Vision Research) provides $1,155,000 in funding to the Augusta University Research Institute, Inc. (doing business as Georgia Health Sciences) to conduct research on targeting the interleukin-6 (IL-6) cis-trans balance in Müller cell dysfunction associated with diabetic retinopathy (DR). The key objectives are to: 1) identify the intracellular signaling mechanisms that lead to differential effects of IL-6 cis- and...
The National Eye Institute (NEI), under the CFDA Program 93.867 Vision Research, awarded a $228,009 Project Grant (R21EY035454) to the Regents of the University of Minnesota. The grant funds a 2-year exploratory research project to assess two mechanistically differentiated approaches to inhibit the STING protein as a potential treatment for diabetic retinopathy (DR). The first aim is to evaluate small molecule-induced STING degradation using proteolysis-targeting chimeras (PROTACs), an...
This Project Grant award from the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), supports research to investigate the role of myeloid cell transmigration in the progression of non-proliferative diabetic retinopathy. The project aims to determine whether blocking myeloid cell infiltration can halt inflammation and disease progression in the retina, as well as evaluate the impact of disrupting leukocyte-endothelial interactions on diabetic...